Login to Your Account

Big Data Year Ahead

Merrimack: Bispecific Antibody Starts Phase II Gastric Program

By Randy Osborne
Staff Writer

Tuesday, July 23, 2013

While investors wait for key data from a Phase II trial with Merrimack Pharmaceuticals Inc.'s HER2 signaling inhibitor MM-121 in breast, ovarian and non-small-cell lung cancer (NSCLC), the company began a Phase II trial with its bispecific antibody, MM-111, which targets the HER2 and HER3 receptors, for advanced gastric, esophageal and gastroesophageal junction (GEJ) cancers.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription